title: [Our experience with targeted therapy in glioblastoma multiforme].
abstract: Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor in adults. The current standard therapy includes surgical resection or biopsy, followed by a combination of radiation and chemotherapy with temozolomide. After progression or recurrence there is only one recommended effective therapy, bevacizumab. Bevacizumab is a monoclonal VEGF inhibitor antibody, inhibiting the angiogenesis in highly vascularized tumors. Resent studies focused on adjuvant treatment with targeted therapy in newly diagnosed tumors. Our purpose is to evaluate the data from patients treated in our department investigate the clinical response and side effects profile and to compare these data with the international results. The applied protocol was well tolerated and side effects corresponded to the already reported ones. The median PFS and survival data correlate with those in the literature. The AVAglio study demonstrated that the addition of bevacizumab to the adjuvant therapy increased PFS significantly.
authors.affiliation: Onkológiai Osztály, MH Egészségügyi Központ, Budapest, Hungary. edina.kiss.dobos@gmail.com.
authors.forename: Edina
authors.initials: E
authors.lastname: Kiss
authors.affiliation: Onkológiai Osztály, MH Egészségügyi Központ, Budapest, Hungary. edina.kiss.dobos@gmail.com.
authors.forename: Erika
authors.initials: E
authors.lastname: Lahm
authors.affiliation: Onkológiai Osztály, MH Egészségügyi Központ, Budapest, Hungary. edina.kiss.dobos@gmail.com.
authors.forename: József
authors.initials: J
authors.lastname: Vachaja
authors.affiliation: Onkológiai Osztály, MH Egészségügyi Központ, Budapest, Hungary. edina.kiss.dobos@gmail.com.
authors.forename: Péter
authors.initials: P
authors.lastname: Nagy
authors.affiliation: Idegsebészeti Osztály, MH Egészségügyi Központ, Budapest, Hungary.
authors.forename: Péter
authors.initials: P
authors.lastname: Bazsó
authors.affiliation: Idegsebészeti Osztály, MH Egészségügyi Központ, Budapest, Hungary.
authors.forename: Zsolt
authors.initials: Z
authors.lastname: Fekete
authors.affiliation: Sugárterápiás Osztály, Országos Onkológiai Intézet, Budapest, Hungary.
authors.forename: Zoltán
authors.initials: Z
authors.lastname: Takácsi-Nagy
authors.affiliation: Onkológiai Osztály, MH Egészségügyi Központ, Budapest, Hungary. edina.kiss.dobos@gmail.com.
authors.forename: Zsuzsanna
authors.initials: Z
authors.lastname: Pápai
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D001932:Brain Neoplasms / Q000378:metabolism* / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D003606:Dacarbazine / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D005909:Glioblastoma / Q000378:metabolism* / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D058990:Molecular Targeted Therapy / Q000379:methods*; D019635:Neurosurgical Procedures / Q000379:methods; D018714:Radiotherapy, Adjuvant; D000077204:Temozolomide; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D003606:Dacarbazine; D000077204:Temozolomide